Bairong R. Xia
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.
Journal: American journal of hematology
Published: April 21, 2026
Chinese Expert Consensus on GnRH-a in Obstetrics and Gynecology
Journal: Zhonghua fu chan ke za zhi
Published: December 28, 2025
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial.
Journal: Therapeutic advances in medical oncology
Published: September 21, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Neoadjuvant therapy in ovarian cancer: Emerging paradigms and therapeutic frontiers.
Journal: Critical reviews in oncology/hematology
Published: April 24, 2025
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Journal: Nature communications
Published: April 21, 2025
Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study.
Journal: International journal of medical sciences
Published: November 22, 2024
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
Journal: Med (New York, N.Y.)
Published: October 22, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Journal: Lancet (London, England)
Published: August 28, 2024
Unraveling the biological functions of UCEC: Insights from a prognostic signature model.
Journal: Computational biology and chemistry
Published: June 02, 2024
Last Updated: 09/26/2026